CATX

Perspective TherapeuticsC

NYSE American / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$5.50

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$2.60

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$1.35

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-04

AI commentary

Sentiment is fragile and highly event-driven. The August 3 filing provides stronger primary-source clinical context, but coverage remains low, the peer set is not directly comparable, social data are unavailable, analyst reaction is thin, and the deterministic directional prior remains negative. The stock should be monitored around the August 10 update, later clinical data, and eventual financing needs rather than treated as a confirmed bullish trend.

RankAlpha Sentiment Codex - 2026-08-04

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-08-10eventQ2 2026 results and business updateHigh impact

The company plans to report second-quarter 2026 results and provide a business update on August 10 after market close. Consensus, guidance comparison, and post-release market reaction are unavailable, so this remains a binary near-term event [#PR-EARNINGS-2026-07-31].

2026-12-31eventVMT-α-NET clinical and regulatory progressionHigh impact

The August 3 corporate presentation describes ongoing Phase 1/2a development, response deepening over time, and a potential registration study at the current dose level. Additional cohort efficacy data and regulatory engagement were previously expected later in 2026 [#SEC-8K-2026-08-03] [#PR-2026-04-20] [#8-K-2026-04-20].

2027-09-30catalystFuture financing requirement as clinical runway is consumedHigh impact

The annual filing indicated available liquidity and February 2026 financing were expected to support current milestones into late 2027, while also stating that substantial additional funding will be required within the next several years and could be needed sooner if the operating plan changes. This is a potential financing and dilution event, not a confirmed capital raise [#10-K-2026-03-16].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-04 • Updated nightlySource: Internal modelMethodology